Drug profile · INN
imciromab pentetate
MYOSCINT
imciromab pentetate (MYOSCINT) is a diagnostic (monoclonal antibody that is labelled with indium (111in) for imaging). Current US regulatory status: approved.
Drug details — imciromab pentetate
- US status
- approved
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.81
Quick answer
imciromab pentetate (MYOSCINT) is a diagnostic (monoclonal antibody that is labelled with indium (111in) for imaging). Current US regulatory status: approved.
Key facts
Mechanism of action
Diagnostic (monoclonal antibody that is labelled with Indium (111In) for imaging)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is imciromab pentetate?
imciromab pentetate (MYOSCINT) is a diagnostic (monoclonal antibody that is labelled with indium (111in) for imaging). Current US regulatory status: approved.
What is the brand name for imciromab pentetate?
MYOSCINT is a marketed brand name for imciromab pentetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of imciromab pentetate?
imciromab pentetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.